Cyclophosphamide Injection
NDC Package 55150-271-99
Package Information
Cyclophosphamide injection is cyclophosphamide is used to treat various types of cancer. This formulation utilizes a injection delivery system. Marketed by Eugia Us Llc, this product is identified by NDC 55150-271 and is authorized under FDA application NDA210735.
Identification & Billing
- RxCUI: 2386859 - cycloPHOSphamide 200 MG/ML Injectable Solution
- RxCUI: 2386859 - cyclophosphamide 200 MG/ML Injectable Solution
- RxCUI: 2568661 - cycloPHOSphamide 1 G in 5 ML Injection
- RxCUI: 2568661 - 5 ML cyclophosphamide 200 MG/ML Injection
- RxCUI: 2568661 - cyclophosphamide 1 G per 5 ML Injection
Clinical Specifications
Regulatory & Marketing
Hierarchy Structure
- 55150 - Eugia Us Llc
- 55150-271 - Cyclophosphamide
- 55150-271-99 - 1 VIAL, MULTI-DOSE in 1 CARTON / 5 mL in 1 VIAL, MULTI-DOSE
- 55150-271 - Cyclophosphamide
The NDC Directory contains ONLY information on final marketed drugs submitted to FDA electronically by labelers. A labeler might be a manufacturer, re-packager or re-labeler. The product information included in the NDC directory does not indicate that FDA has verified the information provided by the product labeler. Assigned NDC numbers are not in any way an indication of FDA approval of the product.
* Please review the full disclaimer at the bottom of this page.
Billing & HCPCS Mapping
To facilitate insurance claims and reimbursement, this drug package is mapped to specific HCPCS administrative codes. This crosswalk aligns clinical data with the billing standards used in ASP (Average Sales Price), AWP, and OPPS payment systems. Use the cards below to identify the correct billable units for provider claims.
Note for Medical Coders: These mappings are synthesized from various CMS datasets including OPPS, PrEP, and DAC (Data Analysis and Coding) contractors. Always confirm unit conversions against the current quarter's pricing files before final submission.
* Please review the full disclaimer at the bottom of this page.
Other Available Packages
The following commercial packages are registered under the same Product NDC (55150-271). Click a package code to view its specific billing and regulatory data.
* Please review the full disclaimer at the bottom of this page.
Frequently Asked Questions
What is the distribution configuration for this product package?
The code 55150-271-99 identifies a specific commercial package of 1 vial, multi-dose in 1 carton / 5 ml in 1 vial, multi-dose of Cyclophosphamide, a human prescription drug labeled by Eugia Us Llc. This injection is formulated for intravenous use and contains cyclophosphamide as the active substance.
Is this product currently listed with the FDA?
Yes, this product is active and verified within the NDC Directory. It was introduced to the market by Eugia Us Llc on August 25, 2021. The current certification is valid through December 31, 2026.
What are the primary indications for this medication?
Cyclophosphamide is used to treat various types of cancer. It is a chemotherapy drug that works by slowing or stopping cell growth. Cyclophosphamide also works by decreasing your immune system's response to various diseases. It is used to treat a certain type of kidney disease in children after other treatments have not worked.
How is this Eugia Us Llc product billed for insurance claims?
For medical billing and reimbursement, this package follows the 11-digit CMS format: 55150027199. Quantities are measured in per "ml or milliliter", products billed per milliliter are usually products measured by liquid volume.. The table below illustrates the segment conversion from the 10-digit labeler code to the 11-digit provider format.
11-Digit Code Conversion
Billing payers usually require a 5-4-2 segment configuration. Below is the conversion from the 10-digit package format to the 11-digit billing format:
Note: The zero is added to the Product segment to maintain the 5-4-2 structure.